Once relatively niche medications for managing Type 2 diabetes, GLP-1 receptor agonists—drugs like Ozempic, Wegovy, Mounjaro, and Zepbound—have exploded in popularity for their ability to promote weight loss and improve metabolic health. They’ve also triggered one of the biggest conversations in employer-sponsored benefits in years.
Are they the key to improving employee health, reducing long-term claims, and increasing productivity? Or are they a fast track to ballooning health insurance costs?
The answer: It depends on how your plan is structured—and how proactive you’re willing to be.
What Are GLP-1s, and Why the Hype?
GLP-1s (glucagon-like peptide-1 receptor agonists) mimic a natural hormone in the body that helps regulate blood sugar and appetite. In addition to their success in treating diabetes, recent studies have shown dramatic weight loss result, 10–20% of body weight in many cases, and even improvements in cardiovascular outcomes.
This has made them appealing to a much broader population, including those who are overweight but not diabetic.
From an employee wellness perspective, GLP-1s can help address:
• Obesity and related comorbidities (heart disease, sleep apnea, hypertension)
• Insulin resistance and pre-diabetes
• Health-related absenteeism and presenteeism
• Long-term disability risk
• But there’s a financial catch—and it’s big.
The Cost Challenge for Employer Health Plans
GLP-1 medications are among the most expensive prescription drugs currently on the market. Monthly costs range from $900 to $1,300 per employee, and some prescriptions extend for years. Unlike acute medications, GLP-1s are often taken long-term, which creates compounding costs.
If 5% of your employee population were prescribed these medications, your pharmacy spend could increase by six figures annually, depending on plan size.
Add to that:
• Unclear guidance from pharmacy benefit managers (PBMs)
• Lack of standard medical necessity protocols
• Pressure from employees demanding coverage for weight loss purposes
• A rapidly evolving regulatory landscape
• All of this puts employers in a difficult position.
Strategic Questions to Ask
If you’re an HR leader, CFO, or plan sponsor, here are a few key questions to guide your approach:
1. Is our plan currently covering GLP-1s? If so, under what criteria?
Some plans cover only for diabetes. Others allow weight loss coverage if comorbidities are present. Knowing your baseline is essential.
2. How much has our pharmacy spend changed in the past 12–18 months?
Tracking this trend can uncover hidden drivers behind your rising claims—and prompt deeper evaluation.
3. Do we have access to condition management programs or clinical oversight?
GLP-1s are far more effective when paired with coaching, nutrition support, and behavioral health. Employers that bundle these services often see better outcomes and engagement.
4. What guardrails can we put in place?
Prior authorization, BMI thresholds, comorbidity requirements, and defined duration limits can help control unnecessary use and costs.
5. Are our employees being educated about the risks and benefits?
These drugs are not a silver bullet. Side effects are common, long-term outcomes are still being studied, and lifestyle changes are still essential.
Potential Impacts on Your Health Insurance Strategy
Here’s where GLP-1s may hit your plan the hardest—and where you have leverage:
1. Pharmacy Trend Increases
Expect double-digit increases to pharmacy spend if demand for GLP-1s is not managed. If your PBM hasn’t flagged this yet, it’s time to ask them to model the impact.
2. Renewal Volatility
Plans offering broad GLP-1 access may face sharper premium increases at renewal. Insurers and stop-loss carriers are watching this trend closely and adjusting underwriting accordingly.
3. Employee Expectations
As these medications become more mainstream (and social media-fueled), employees are increasingly aware of them. Not covering GLP-1s may trigger frustration, especially if competitors do.
4. Equity & Compliance Considerations
Employers that offer wellness programs or weight management incentives may need to re-evaluate them under new ADA and EEOC guidance, particularly when prescription-based interventions enter the mix.
Bottom Line: Balance Innovation With Oversight
GLP-1s represent a powerful new tool in chronic disease and obesity management—but they’re not without consequences. As an employer, your goal isn’t just to follow trends; it’s to make informed, sustainable decisions that benefit both your employees and your bottom line.
Consider taking a phased approach:
• Conduct a claims and cost impact analysis
• Consult with your advisor or PBM about prior authorization protocols
• Explore wraparound services like lifestyle coaching or condition management
• Communicate clearly with employees about what’s covered—and why
The GLP-1 wave isn’t going away. But with the right strategy, it doesn’t have to sink your plan.
Want help evaluating the impact of GLP-1s on your health insurance plan? McConkey’s employee benefits consultants can help you make sense of the data, design meaningful guardrails, and support employee wellness—without losing sight of your financial goals.
